233 related articles for article (PubMed ID: 32415240)
21. Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5 years of follow-up from Fight Retinal Blindness registry.
Sánchez-Monroy J; Nguyen V; Puzo M; Calvo P; Arruabarrena C; Monaco P; Chilov M; Keegan D; Barthelmes D; Gillies M
Acta Ophthalmol; 2023 Jun; 101(4):457-464. PubMed ID: 36536538
[TBL] [Abstract][Full Text] [Related]
22. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
23. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
[TBL] [Abstract][Full Text] [Related]
24. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
Bailey C; Scott LJ; Rogers CA; Reeves BC; Hamill B; Peto T; Chakravarthy U; Harding SP;
Ophthalmology; 2019 Jan; 126(1):75-86. PubMed ID: 30301555
[TBL] [Abstract][Full Text] [Related]
25. Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
Daniel E; Maguire MG; Grunwald JE; Toth CA; Jaffe GJ; Martin DF; Ying GS;
JAMA Ophthalmol; 2020 May; 138(5):510-518. PubMed ID: 32191267
[TBL] [Abstract][Full Text] [Related]
26. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
27. The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.
Cheung CMG; Grewal DS; Teo KYC; Gan A; Mohla A; Chakravarthy U; Wong TY; Jaffe GJ
Ophthalmol Retina; 2019 Dec; 3(12):1045-1055. PubMed ID: 31444144
[TBL] [Abstract][Full Text] [Related]
28. Significance of the hyperautofluorescent ring associated with choroidal neovascularisation in eyes undergoing anti-VEGF therapy for wet age-related macular degeneration.
Camacho N; Barteselli G; Nezgoda JT; El-Emam S; Cheng L; Bartsch DU; Freeman WR
Br J Ophthalmol; 2015 Sep; 99(9):1277-83. PubMed ID: 25777818
[TBL] [Abstract][Full Text] [Related]
29. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
30. Smoking and treatment outcomes of neovascular age-related macular degeneration over 12 months.
Detaram HD; Joachim N; Liew G; Vu KV; Burlutsky G; Mitchell P; Gopinath B
Br J Ophthalmol; 2020 Jul; 104(7):893-898. PubMed ID: 31558491
[TBL] [Abstract][Full Text] [Related]
31. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
[TBL] [Abstract][Full Text] [Related]
32. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
33. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
34. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
Hata M; Yamashiro K; Ooto S; Oishi A; Tamura H; Miyata M; Ueda-Arakawa N; Takahashi A; Tsujikawa A; Yoshimura N
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):292-298. PubMed ID: 28114590
[TBL] [Abstract][Full Text] [Related]
35. Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration: AREDS2 Report 24.
Hwang CK; Agrón E; Domalpally A; Cukras CA; Wong WT; Chew EY; Keenan TDL;
Ophthalmol Retina; 2021 Feb; 5(2):108-117. PubMed ID: 33075546
[TBL] [Abstract][Full Text] [Related]
36. Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization.
Yoon W; Yoon J; Na SK; Lee J; Kim J; Kim JW; Cho HJ
Sci Rep; 2021 Dec; 11(1):23643. PubMed ID: 34880302
[TBL] [Abstract][Full Text] [Related]
37. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.
Berg K; Roald AB; Navaratnam J; Bragadóttir R
Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190
[TBL] [Abstract][Full Text] [Related]
38. Association of Vascular Versus Avascular Subretinal Hyperreflective Material With Aflibercept Response in Age-related Macular Degeneration.
Kawashima Y; Hata M; Oishi A; Ooto S; Yamashiro K; Tamura H; Miyata M; Uji A; Ueda-Arakawa N; Tsujikawa A
Am J Ophthalmol; 2017 Sep; 181():61-70. PubMed ID: 28669776
[TBL] [Abstract][Full Text] [Related]
39. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
40. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
